Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Altimmune, Inc.NASDAQ: ALT

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables dips below year-ago levels

Q1 FY2026 accounts receivables of $72K fell 94.6% year over year, behind the +2450.0% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -14.5% a year.

Context

  • Accounts receivables amounted to 5026.8% of revenue in FY2025, down 3653.2 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -94.6% toward the trailing-twelve-month pace of +2450.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$72K+120.9% QoQ
Last fiscal yearDec 2025
$2.06M+18.7% YoY
LTMMar 2026
$799K+2450.0% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-94.6%——
1 year+18.7%——
3-year CAGR-14.5%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
2.06M USD
Year-over-year change
+18.7%
4-year CAGR
-25.1%

Accounts Receivables vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2450.0% is the 2nd highest of 6, against a peer median of -70.9%.
  • Accounts receivables amounts to 2219.4% of revenue for ALT, versus a peer median of 18.2%.
ALT Competitors
Accounts Receivables for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$177.45M USD-18642.7%—92.7%
GPCRStructure Therapeutics Inc.LTM Jun 2026$100.3M USD———
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$32.8M USD+4000.1%+39.1%47.4%
IVAInventiva S.A.FY2025€816.45K EUR-70.9%-40.3%18.2%
ALTAltimmune, Inc.LTM Mar 2026$799K USD+2450.0%-14.5%2219.4%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$451K USD-1148.8%+17.0%0.6%
VIRVir Biotechnology, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ALT) —-70.9%+17.0%18.2%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Depreciation & Amortization551K493K477K238K112K
Deferred Income Tax0000(681K)
Stock-Based Compensation5.52M8.1M10.64M14.39M16.08M
Change in Working Capital(251K)14.11M(8.27M)4.48M6.75M
Accounts Receivables6.53M3.3M(2.31M)1.74M2.06M
Inventory00000
Accounts Payables1.42M2.77M(2.73M)(1.86M)2.51M
Other Working Capital(8.21M)8.04M(3.23M)4.6M2.19M
Other Non-Cash Items13.03M(578K)9.79M(3.9M)(1.7M)
Operating Cash Flow(78.24M)(62.59M)(75.81M)(79.85M)(67.54M)
Capital Expenditures(12.31M)(126K)(47K)0(11K)
Acquisitions (Net)00000
Purchases of Investments(7.59M)(73.27M)(88.63M)(115.73M)(285.45M)
Sales of Investments107.43M0102.41M87.35M152.99M
Other Investing Activities(195K)0000
Investing Cash Flow87.52M(73.4M)13.73M(28.39M)(132.47M)
Debt Repayment000033.92M
Common Stock Issued65.04M56.35M86.6M9.99M173.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities58K434K(496K)50K(709K)
Financing Cash Flow65.1M56.78M86.11M10.04M206.84M
Effect of Forex Changes00000
Net Change in Cash74.38M(79.2M)24.03M(98.19M)6.83M
Free Cash Flow(90.55M)(62.71M)(75.86M)(79.85M)(67.55M)

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.